Financial Performance - Net revenue increased by 29% YoY to R$5635 million, excluding non-recurring effects, construction, and financial asset bifurcation[15, 17] - Adjusted EBITDA increased by 215% YoY to R$3617 million, excluding non-recurring effects, construction, and financial asset bifurcation[15, 19] - Net income increased significantly by 766% YoY to R$2136 million[15, 43] - Cash flow from operations increased by 794% YoY to R$3181 million[15] - Cash conversion rate improved from 595% to 879%[15] Operational Highlights - Water production volume increased by 48% YoY[10] - Water connections increased by 08% YoY[12] - Sewage connections increased by 11% YoY[13] Revenue Analysis - FAUSP price contributed R$290 million to revenue[23] - Volume contributed R$210 million to revenue[23] - Mix impact reduced revenue by R$138 million, mainly due to subsidized tariffs[23, 31] Cost Management - Personnel expenses decreased by R$77 million, a 103% reduction YoY, due to an 11% reduction in employee numbers[34, 39] - Energy expenses decreased by 37% YoY[34] Capex and Debt - Capex reached R$36 billion in 2Q25[79] - Debt issued in July 2025 included R$11 billion in Eco Invest 2032, R$10 billion in Eco Invest 2035, and R$28 billion in Blue Bond 2030[62] - Cash position as of July 2025 was R$129 billion[64] Key Ratios - Return on Invested Capital (ROIC) increased to 15%[66] - Return on Equity (ROE) increased to 13%[66]

August 12, 2025 Second Quarter 2025 Financial Results Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Mick McCloskey Vice President, Treasury & Investor Relations To participate via phone, please dial: 1-201-689-8345 4 2 Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private S ...

Second Quarter Earnings Presentation August 2025 Important notice Cautionary Note Regarding Forward-Looking Statements and Projections. Certain statements in this presentation may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, each as amended. Forward-looking statements provide current expectations of future events and include any statement th ...

Financial Performance - Q4 FY25 - Revenue remained flat at $60.159 billion[9] - Gross margin increased by 17% to $2.202 billion[9] - Operating earnings increased by 7% to $428 million on a GAAP basis and 19% to $719 million on a non-GAAP basis[9] - Net earnings increased by 2% to $239 million on a GAAP basis and 11% to $501 million on a non-GAAP basis[9] - Diluted EPS increased by 4% to $1.00 on a GAAP basis and 13% to $2.08 on a non-GAAP basis[9] Segment Performance - Q4 FY25 - Pharmaceutical and Specialty Solutions revenue decreased by 0% to $55.372 billion, while segment profit increased by 11% to $535 million[11] - Global Medical Products and Distribution revenue increased by 3% to $3.199 billion, and segment profit increased significantly by 49% to $70 million[15] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 37% to $1.609 billion, with segment profit increasing by 44% to $160 million[20] Financial Performance - FY25 - Revenue decreased by 2% to $222.578 billion[28] - Gross margin increased by 10% to $8.168 billion[28] - Operating earnings increased significantly by 83% to $2.275 billion on a GAAP basis and 15% to $2.786 billion on a non-GAAP basis[28] - Net earnings increased significantly by 83% to $1.561 billion on a GAAP basis and 7% to $1.995 billion on a non-GAAP basis[28] - Diluted EPS increased significantly by 87% to $6.45 on a GAAP basis and 9% to $8.24 on a non-GAAP basis[28] Segment Performance - FY25 - Pharmaceutical and Specialty Solutions revenue decreased by 3% to $204.644 billion, but segment profit increased by 12% to $2.258 billion[30] - Global Medical Products and Distribution revenue increased by 2% to $12.636 billion, with segment profit increasing significantly by 47% to $135 million[35] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 19% to $5.382 billion, and segment profit increased by 22% to $516 million[40] FY26 Outlook - Non-GAAP EPS is expected to be in the range of $9.30 - $9.50, revised from the previous outlook of $9.10 to $9.30[48] - Interest and Other expenses are projected to be approximately $275 million[48] - Non-GAAP adjusted free cash flow is expected to be between $2.75 billion and $3.25 billion[48]

Q2 2025 Key Performance Highlights - Funded Accounts reached 363 million, a 14% year-over-year increase[12] - Assets Under Administration (AUA) totaled $175 billion, up 54% year-over-year[12] - Net Contribution amounted to $210 million, reflecting a 26% year-over-year growth[12] - Adjusted EBITDA was $72 million, a 31% increase compared to the previous year[12] Business Strategy and Product Updates - The company is focused on four strategic pillars: Trading, Investing, Wealth Management, and Neo-Banking, to drive global expansion and product localization[15, 16, 17, 18, 19] - New product launches include 24/5 trading for U S equities and futures, new Smart Portfolios with Franklin Templeton, French savings products, and the eToro Card now available in multiple E U markets[22, 23, 26, 27] - The company is expanding its crypto offering in the U S, providing access to over 100 tokens[28] - The company launched Tori, an AI analyst providing personalized investment insights[29] Financial Performance Details - Net Trading Contribution from Equities, Commodities, and Currencies was $114042 thousand for the three months ended June 30, 2025[123] - Revenue from Cryptoassets was $1914792 thousand for the three months ended June 30, 2025[123] - Net income for Q2 2025 was $30185 thousand, which includes $15 million of IPO and other related costs[110, 130]

Liquidia Corporation 2Q2025 Financial Results & Corporate Update August 12, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 3 Rapid adoption over last 11 weeks! As of August 8, 2025 This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements ...

Financial Performance - AUCATZYL net product sales reached $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025[8] - The company's cash, cash equivalents, and marketable securities totaled $454.3 million as of June 30, 2025[24] - Cost of sales for Q2 2025 was $24.445 million[24] - Research and development expenses, net for Q2 2025 were $27.430 million[24] - Selling, general, and administrative expenses for Q2 2025 were $30.265 million[24] - Loss from operations for Q2 2025 was $61.217 million[24] - Total comprehensive loss for Q2 2025 was $28.949 million[24] AUCATZYL Commercialization and Market Access - 46 treatment centers are authorized for AUCATZYL as of August 12, 2025[8] - Over 90% of total U S medical lives are covered for AUCATZYL[10] Obe-cel Clinical Data and Development - At 3 years of follow-up, 38.4% of responders remain in remission without subsequent treatment[14, 15] - The probability of remaining in remission after 24 months was 54.1% censoring for consolidative SCT[17] - At 24 months, overall survival probability was 46.0%[19] Upcoming Milestones - Initial data from PY01 trial in pediatric ALL is expected in H2 2025[27]

Commercial Performance - 2Q 2025 net product revenues reached $18.1 million, a 6.2% increase compared to $17.0 million in the same quarter of 2024 [16, 58] - Total 1H 2025 net product revenue was $35.5 million, up from $34.9 million during the 1H of 2024 [16] Pipeline Progress - LOTIS-7 data showed a 93.3% ORR (Overall Response Rate) and an 86.7% CR (Complete Response) rate across 30 efficacy evaluable patients when ZYNLONTA was combined with glofitamab [16, 53] - Updated MZL IIT data presented at ICML demonstrate an 85% ORR and a 69% CR rate [16] - LOTIS-5 is on track to reach pre-specified PFS (Progression-Free Survival) events by the end of 2025 [16] Corporate Update - The company secured $100 million in private placement, extending the expected cash runway into 2028 [16] - A strategic prioritization was implemented, resulting in a 30% reduction in force and one-time charges of $13.1 million, including $6.7 million in employee severance and $6.4 million in non-cash impairment of assets related to the UK facility closure [16] - The company's cash balance was $264.6 million as of June 30, 2025 [16, 58] LOTIS-7 Trial Safety - In the LOTIS-7 Phase 1b trial, 56.1% of patients experienced Grade 3/4 TEAEs (Treatment-Emergent Adverse Events) [47] - Cytokine Release Syndrome (CRS) of any grade was observed in 39% of patients [49] - ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) of any grade was observed in 7.3% of patients [49] ZYNLONTA Market Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL (Diffuse Large B-Cell Lymphoma) and indolent lymphomas [21, 22]

Second Quarter 2025 Earnings Presentation August 12th, 2025 Disclaimer Forward-Looking Statements. This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from the statements made herein. All statements other than statements of historical fact included in this presentation are forward-lookin ...

August 2025 1 INVESTOR PRESENTATION - MAY 2025 DISCLAIMER TAT Technologies Ltd. (together with its subsidiaries, the "Company", "we", "our" or "us") has filed a registration statement (including a preliminary prospectus) with the U.S. Securities and Exchange Commission (the "SEC") for the offering to which this presentation relates. The registration statement has not yet become effective. The securities proposed to be offered pursuant to such registration statement may not be sold, nor may offers to buy be ...